Research
Hormonal
GLP-1 receptor agonists (specifically semaglutide and liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant, dose-dependent weight loss in patients with type 2 diabetes, making them superior to weight-gain-promoting medications like insulin and sulfonylureas for weight-centric management.
If you have Type 2 Diabetes and struggle with weight, ask your doctor about GLP-1 agonists (like semaglutide) or dual agonists (like tirzepatide). These drugs not only control blood sugar but also promote significant weight loss (up to 15-20% in trials) by slowing digestion and reducing appetite, unlike older drugs like insulin which often cause weight gain.
StrongSupportsHIGH confidence
GLP-1 agonists (i.e., liraglutide and semaglutide) are the only anti-diabetic medications to be FDA approved for weight loss as well... Weekly subcutaneous of 2.4 mg semaglutide injections resulted in 15.8% of total body weight loss percentage (TBWL%) compared to 6.4% with daily injections of liraglutide 3.0 mg... Tirzepatide 15 mg was 20.9% (p < 0.001 for all comparisons with placebo)
Why this rating
Based on multiple systematic reviews, meta-analyses, and randomized clinical trials (RCTs) cited in the text.
Source
Weight-centric treatment of type 2 diabetes mellitus
Wissam Ghusn et al. · Obesity Pillars · 2022
narrative_reviewCited 38×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →